TRISTEL PLC

Share Issue/Capital Change • Feb 17, 2022

National Storage Mechanism | Additional information

RNS Number : 0475C

Tristel PLC

17 February 2022

Tristel plc

("Tristel", the "Company" or the "Group")

Exercise of Share Options and Total Voting Rights

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products utilising proprietary chlorine dioxide technology announces that it has issued and allotted a total of 10,000 new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") following the exercise of options by employees of the Group. 

Application has been made to the London Stock Exchange for the 10,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 23 February 2022.

After Admission, the total number of Ordinary Shares in issue will be 47,195,043 and the total number of voting rights will therefore be 47,195,043. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules. 

Tristel plc	www.tristel.com
Paul Swinney, Chief Executive	Tel: 01638 721 500
Liz Dixon, Finance Director
finnCap Limited - Nominated Adviser and Broker
Geoff Nash / Charles Beeson, Corporate Finance	Tel: 020 7220 0500
Alice Lane, Corporate Broking
Walbrook PR Ltd	tristel@walbrookpr.com                               Tel: 020 7933 8780
Paul McManus	Mob: 07980 541 893
Lianne Cawthorne	Mob: 07584 391 303

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEBSGDDLUBDGDR